pmlive.com
Cure8 news brief
Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease
Medications
Guselkumab
Ustekinumab
IL-23 inhibitor
IL-12/23 inhibitor
Abdominal Pain
Rectal Bleeding
Weight Loss
Why This Matters
A new FDA approval expands treatment options for adults with moderately to severely active Crohn’s disease, including a fully subcutaneous IL-23 inhibitor regimen that could offer more flexibility. The approval was based on phase 3 trials and may be relevant for people who failed or were intolerant to prior therapies.
Who Should Pay Attention
Adults with Crohn’s disease, patients who have failed or are intolerant to other biologics or conventional therapies, clinicians treating IBD, and researchers following new IBD drug approvals.
Study Snapshot
Story typeResearch news
Evidence typeFDA Approval
Source depthFull source text
What To Know
The FDA has approved guselkumab (Tremfya) for adults with moderately to severely active Crohn’s disease. The company emphasizes the availability of a fully subcutaneous induction regimen as a new option. The approval is based on phase 3 trial data including more than 1,300 patients and the GRAVITI programme, per the article.
The piece quotes investigators and company representatives describing endoscopic remission outcomes and treatment flexibility.
Practical points: This is regulatory news about a newly approved treatment option; it does not provide prescribing guidance, safety details, or head-to-head comparative effectiveness data beyond the article’s mention of pooled trial endpoints.
Patients should discuss with their gastroenterology team whether this option is appropriate for their individual disease history and prior treatments.
Keep In Mind
This article reports regulatory approval and summarizes trial program names and company statements. It does not include detailed safety data, full trial results, or prescribing information. New approvals can affect access and insurance coverage, but individual suitability and timing of use depend on clinician judgement and local formularies.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationpmlive.com
Indexed viaBing News
Source typeResearch news
PublishedMar 21, 2025, 5:24 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Johnson & Johnson's Tremfya recommended by CHMP to treat Crohn's disease - PMLiVE
A CHMP recommendation is a major regulatory step toward EU approval — that could mean a new biologic option (guselkumab/Tremfya) for adults with moderate–severe Crohn’s disease, including people who haven’t responded to...
J&J's Stelara granted EC approval to treat Crohn's disease in paediatric patients - PMLiVE
This EC approval means ustekinumab (Stelara) is now an authorised treatment option in the EU for certain children and adolescents with moderate–severe Crohn’s disease who have not responded to other treatments.
Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease
A CHMP positive opinion means guselkumab (Tremfya) could become an approved treatment option for adults with moderately to severely active Crohn’s disease in the EU, offering both IV and SC induction routes. This could...